My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 102

    1.

    New definition for the partial remission period in children and adolescents with type 1 diabetes.

    Mortensen HB, Hougaard P, Swift P, Hansen L, Holl RW, Hoey H, Bjoerndalen H, de Beaufort C, Chiarelli F, Danne T, Schoenle EJ, Aman J; Hvidoere Study Group on Childhood Diabetes.

    Diabetes Care. 2009 Aug;32(8):1384-90. Epub 2009 May 12.PMID: 19435955 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus.

    Bonfanti R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E, Meschi F, Bosi E, Chiumello G, Bonifacio E.

    Diabet Med. 1998 Oct;15(10):844-50.PMID: 9796885 [PubMed - indexed for MEDLINE]Related articles

    3.

    Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents.

    Böber E, Dündar B, Büyükgebiz A.

    J Pediatr Endocrinol Metab. 2001 Apr;14(4):435-41.PMID: 11327378 [PubMed - indexed for MEDLINE]Related articles

    4.

    Young children (<5 yr) and adolescents (>12 yr) with type 1 diabetes mellitus have low rate of partial remission: diabetic ketoacidosis is an important risk factor.

    Bowden SA, Duck MM, Hoffman RP.

    Pediatr Diabetes. 2008 Jun;9(3 Pt 1):197-201.PMID: 18547233 [PubMed - indexed for MEDLINE]Related articles

    5.

    Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group.

    [No authors listed]

    J Clin Endocrinol Metab. 1987 Jul;65(1):30-6.PMID: 2884229 [PubMed - indexed for MEDLINE]Related articles

    6.

    Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes.

    Pfleger C, Mortensen HB, Hansen L, Herder C, Roep BO, Hoey H, Aanstoot HJ, Kocova M, Schloot NC; Hvidøre Study Group on Childhood Diabetes.

    Diabetes. 2008 Apr;57(4):929-37. Epub 2008 Feb 25.PMID: 18299313 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes.

    Picardi A, Visalli N, Lauria A, Suraci C, Buzzetti R, Merola MK, Manfrini S, Guglielmi C, Gentilucci UV, Pitocco D, Crinò A, Bizzarri C, Cappa M, Pozzilli P.

    Horm Metab Res. 2006 Oct;38(10):668-72.PMID: 17075776 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.

    [No authors listed]

    Ann Intern Med. 1998 Apr 1;128(7):517-23.PMID: 9518395 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--"Flatbush diabetes".

    Banerji MA.

    J Pediatr Endocrinol Metab. 2002 Apr;15 Suppl 1:493-501. Review.PMID: 12017222 [PubMed - indexed for MEDLINE]Related articles

    10.

    The PTPN22 1858T gene variant in type 1 diabetes is associated with reduced residual beta-cell function and worse metabolic control.

    Petrone A, Spoletini M, Zampetti S, Capizzi M, Zavarella S, Osborn J, Pozzilli P, Buzzetti R; Immunotherapy Diabetes (IMDIAB) Group.

    Diabetes Care. 2008 Jun;31(6):1214-8. Epub 2008 Feb 5.PMID: 18252906 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX).

    Crinò A, Schiaffini R, Manfrini S, Mesturino C, Visalli N, Beretta Anguissola G, Suraci C, Pitocco D, Spera S, Corbi S, Matteoli MC, Patera IP, Manca Bitti ML, Bizzarri C, Pozzilli P; IMDIAB group.

    Eur J Endocrinol. 2004 May;150(5):719-24.PMID: 15132730 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    [The role of insulin secretion and insulin resistance in the clinical course of newly diagnosed diabetes mellitus in children]

    Szadkowska A, Pietrzak I, Markuszewski L, Bodalski J.

    Med Wieku Rozwoj. 2005 Apr-Jun;9(2):223-34. Polish. PMID: 16085963 [PubMed - indexed for MEDLINE]Related articles

    13.

    Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.

    Taha DR, Castells S, Umpaichitra V, Bastian W, Banerji MA.

    J Pediatr Endocrinol Metab. 2002 Jan;15(1):59-67.PMID: 11822582 [PubMed - indexed for MEDLINE]Related articles

    14.

    Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.

    Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D, Phillip M, Josefsberg Z.

    Diabetes Metab Res Rev. 2007 May;23(4):286-91.PMID: 17124721 [PubMed - indexed for MEDLINE]Related articles

    15.

    Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study.

    Pozzilli P, Manfrini S, Buzzetti R, Lampeter E, Leeuw ID, Iafusco D, Prisco M, Ionescu-Tirgoviste C, Kolouskovà S, Linn T, Ludvigsson J, Madàcsy L, Mrozikiewicz AS, Mrozikiewicz PM, Podar T, Vavrinec J, Vialettes B, Visalli N, Yilmaz T, Browne PD; IMDIAB group.

    Diabetes Res Clin Pract. 2005 Jun;68(3):258-64. Epub 2004 Nov 21.PMID: 15936469 [PubMed - indexed for MEDLINE]Related articles

    16.

    Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

    Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L.

    N Engl J Med. 2005 Jun 23;352(25):2598-608.PMID: 15972866 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty.

    Bonfanti R, Bognetti E, Meschi F, Brunelli A, Riva MC, Pastore MR, Calori G, Chiumello G.

    Acta Diabetol. 1998 Jul;35(2):91-5.PMID: 9747961 [PubMed - indexed for MEDLINE]Related articles

    18.

    Remission in IDDM: prospective study of basal C-peptide and insulin dose in 268 consecutive patients.

    Agner T, Damm P, Binder C.

    Diabetes Care. 1987 Mar-Apr;10(2):164-9.PMID: 3556104 [PubMed - indexed for MEDLINE]Related articles

    19.

    Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.

    Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D.

    Diabetes Metab Res Rev. 2007 May;23(4):292-8.PMID: 17124720 [PubMed - indexed for MEDLINE]Related articles

    20.

    Natural course of remission in IDDM during 1st yr after diagnosis.

    Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J.

    Diabetes Care. 1992 Jan;15(1):66-74.PMID: 1737543 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity